Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Grows By 8.6%

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 3,150,000 shares, a growth of 8.6% from the November 15th total of 2,900,000 shares. Currently, 6.5% of the shares of the stock are short sold. Based on an average trading volume of 321,400 shares, the short-interest ratio is currently 9.8 days.

Astria Therapeutics Trading Down 3.0 %

Shares of Astria Therapeutics stock opened at $9.52 on Monday. The firm has a market cap of $537.21 million, a PE ratio of -4.56 and a beta of 0.67. The stock has a 50 day moving average of $10.82 and a 200 day moving average of $10.70. Astria Therapeutics has a 12 month low of $5.80 and a 12 month high of $16.90.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ATXS. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Oppenheimer increased their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Astria Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers increased its position in Astria Therapeutics by 4.1% in the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 2,556 shares during the last quarter. Quest Partners LLC grew its stake in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,112 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Astria Therapeutics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after buying an additional 8,965 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Astria Therapeutics by 8.7% in the 3rd quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock worth $1,624,000 after buying an additional 11,763 shares during the last quarter. Finally, PDT Partners LLC purchased a new stake in shares of Astria Therapeutics during the 3rd quarter valued at about $140,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.